Article
Oncology
Max S. Topp, Herbert Eradat, Axel Florschuetz, Andreas Hochhaus, Tomasz Wrobel, Jan Walewski, Wanda Knopinska-Posluszny, Abraham S. Kanate, Ewa Lech-Maranda, Uta Brunnberg, Surya Chitra, Tina G. Nielsen, Gila Sellam, Mahesh Shivhare, Izidore S. Lossos
Summary: This study evaluated the efficacy and safety of two anti-CD20-based triplet combinations for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. The results showed limited efficacy and safety issues with G-atezo-pola in patients with relapsed diffuse large B-cell lymphoma, indicating no further development is planned.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Leyre Bento, Oliver Vogler, Adriana Sas-Barbeito, Josep Muncunill, Teresa Ros, Jordi Martinez, Adriana Quintero-Duarte, Rafael Ramos, Victor Jose Asensio, Concepcion Fernandez-Rodriguez, Antonio Salar, Alfons Navarro, Raquel del Campo, Javier Ibarra, Regina Alemany, Antonio Gutierrez
Summary: This study identified three promising prognostic markers for diffuse large B cell lymphoma (DLBCL) patients at high risk of failure with standard therapy using microarray technology. The importance of these biomarkers in treatment response and survival was validated in both cell lines and patients. This study provides the possibility of early detection for DLBCL patients at high risk of treatment failure.
Review
Biochemistry & Molecular Biology
Bodo C. Melnik, Rudolf Stadler, Ralf Weiskirchen, Claus Leitzmann, Gerd Schmitz
Summary: Epidemiological evidence suggests a link between cow's milk consumption and the risk of DLBCL. This review explores the role of milk-related agents, such as milk-derived exosomes (MDEs) and their microRNAs (miRs), in lymphomagenesis. MDE miRs during breastfeeding can upregulate BCL6 and suppress BLIMP1, promoting B cell proliferation. After weaning, the decline in MDE miR signaling leads to a decrease in BCL6 expression and an increase in BLIMP1-mediated B cell maturation. However, the consumption of pasteurized cow's milk in adults may maintain high BLC6/BLIMP1 ratio and facilitate B cell de-differentiation, potentially contributing to B cell lymphomagenesis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pathology
Ji Yuan, Hui Liu, Shimin Hu, Roberto N. Miranda, Xinjie Xu, Michael G. Bayerl, Cody J. Artymiuk, Holly Berg, Rebecca L. King, Min Shi, Rong He, David Viswanatha, L. Jeffrey Medeiros, Ellen D. Mcphail
Summary: This study reports 5 adult patients with FL and FL/DLBCL with concurrent BCL2 and IRF4 rearrangements. The clinicopathologic and mutational features of these patients are more akin to FL and DLBCL, and should not be characterized as large B-cell lymphoma with IRF4 rearrangement.
Article
Radiology, Nuclear Medicine & Medical Imaging
Lars Kurch, Andreas Huettmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Duehrsen, Dirk Hasenclever
Summary: In diffuse large B-cell lymphoma, continuous scales such as qPET and Delta SUVmax are more suitable for predicting treatment outcomes based on interim PET scans compared to the ordinal Deauville scale. The positive predictive value curves for qPET and Delta SUVmax were found to be similar, with both methods identifying less than 15% of patients as poor responders. The study suggests that continuous scales offer more accurate outcome predictions in this context.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Oncology
Husain Yar Khan, Md. Hafiz Uddin, Suresh Kumar Balasubramanian, Noor Sulaiman, Marium Iqbal, Mahmoud Chaker, Amro Aboukameel, Yiwei Li, William Senapedis, Erkan Baloglu, Ramzi M. Mohammad, Jeffrey Zonder, Asfar S. Azmi
Summary: Targeting PAK4 and NAMPT using the small molecule inhibitor KPT-9274 can inhibit cell proliferation, deplete energy, and induce apoptosis in various NHL subtypes. KPT-9274 treatment shows potent anti-tumor effects in experimental models, suggesting its potential as a novel therapy for NHL.
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Article
Radiology, Nuclear Medicine & Medical Imaging
F. Montes de Jesus, Y. Yin, E. Mantzorou-Kyriaki, X. U. Kahle, R. J. de Haas, D. Yakar, A. W. J. M. Glaudemans, W. Noordzij, T. C. Kwee, M. Nijland
Summary: The study evaluated the use of radiomic features extracted from [F-18]FDG PET/CT using machine learning algorithms to discriminate FL from DLBCL. The Gradient Boosting classifier showed the best discrimination performance, surpassing the SUVmax-based logistic regression model.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Yi Chen, Luting Luo, Lushan Chen, Xiaoyun Zheng, Xiaozhu Yang, Zhihong Zheng, Jing Zheng, Tingbo Liu, Ting Yang, Jianda Hu
Summary: This study aimed to investigate the clinicopathological characteristics and prognosis of patients with co-existing FL and DLBCL components (FL/DLBCL). The results showed that patients with FL/DLBCL had intermediate clinical features between FL and DLBCL, and had inferior treatment response and survival compared to pure FL. However, when receiving the R-CHOP regimen, patients with FL/DLBCL showed similar overall survival to those with DLBCL.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Cell Biology
Eva A. M. Hesius, Lidia van Laar, Margriet Oosterveld, Annemiek B. van Spriel, Blanca Scheijen, Jan Willem Leeuwis, Henri A. M. Marres, Patricia J. T. A. Groenen, Wendy B. C. Stevens, Ellen van Der Spek, Adriaan J. C. van den Brule, Brigiet M. Hoevenaars, Konnie M. Hebeda, Michiel van den Brand
Summary: LBCL-IRF4 is a newly identified subtype of large B cell lymphoma in the 2017 revised WHO classification, initially reported in children. This study aimed to assess the frequency of IRF4 rearrangements in adult DLBCLs that need to be reclassified as LBCL-IRF4 using FISH. Among 238 DLBCL patients, six (including the index patient) were found to have IRF4 rearrangements, and their immunohistochemical profile was consistent with LBCL-IRF4. This study highlights the importance of considering LBCL-IRF4 in older patients and at different anatomical sites.
Review
Oncology
Allison Barraclough, Eliza Hawkes, Laurie H. Sehn, Sonali M. Smith
Summary: Large B-cell lymphoma is the most common lymphoma and has the highest burden of lymphoma-related deaths. Treatment has aimed to achieve a cure with CHOP and rituximab plus CHOP, but not all patients are cured due to the heterogeneity of the disease.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Yan Liang, Zhuo-Jun Yu, Min Liu, Hui-Min Liu, Tao Xiong, Yuan-Yan Tang, Zhi-Ping Huang
Summary: DLBCL is the most common type of non-Hodgkin lymphoma worldwide. Hsa-miR-429 exerts a tumor-suppressive effect by targeting CBX8, which promotes cancer development. Hsa-miR-429 may be a potential diagnostic marker and nucleic acid drug for DLBCL, while CBX8 represents a promising therapeutic target.
MOLECULAR MEDICINE REPORTS
(2021)
Article
Oncology
Jan Duerig, Jens Uhlig, Anke Gerhardt, Markus Ritter, Gunnar Hapke, Joerg Hessling, Peter Staib, Frieder Wolff, Katja Krumm, Ludwig Fischer von Weikersthal
Summary: Subcutaneous rituximab has demonstrated effectiveness and safety in patients with follicular lymphoma and diffuse large B cell lymphoma. Patient and nurse satisfaction with subcutaneous administration was high.
Article
Oncology
Wei Qin, Di Fu, Qing Shi, Lei Dong, Hongmei Yi, Hengye Huang, Xufeng Jiang, Qi Song, Zhenhua Liu, Shu Cheng, Jinyan Huang, Li Wang, Pengpeng Xu, Weili Zhao
Summary: The clinical and molecular characteristics of localized diffuse large B-cell lymphoma with single nodal or single extranodal involvement in the rituximab era are complex and not fully understood. Analysis of clinical features, genetic aberrations, and tumor immunophenotype can guide personalized treatment for localized DLBCL in the future.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pathology
Nelly O. Elshafie, Naila C. do Nascimento, Nathanael I. Lichti, Andrea L. Kasinski, Michael O. Childress, Andrea P. dos Santos
Summary: Lymphoma is a common cancer in dogs, with DLBCL being the predominant type. By studying miRNA signatures, this research aimed to develop molecular diagnostic tools for DLBCL. The results showed downregulation of let-7 family and miR-155, as well as upregulation of miR-34a in DLBCL, with a combination of miR-34a and let-7f achieving 100% differentiation between DLBCL and controls.
VETERINARY PATHOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sebastian C. Warth, Kai P. Hoefig, Anian Hiekel, Sonja Schallenberg, Ksenija Jovanovic, Ludger Klein, Karsten Kretschmer, K. Mark Ansel, Vigo Heissmeyer
Review
Cell Biology
Kai P. Hoefig, Vigo Heissmeyer
JOURNAL OF CELL BIOLOGY
(2018)
Article
Clinical Neurology
Simone Kreth, Elisabeth Limbeck, Ludwig C. Hinske, Stefanie V. Schuetz, Niklas Thon, Kai Hoefig, Rupert Egensperger, Friedrich W. Kreth
ACTA NEUROPATHOLOGICA
(2013)
Review
Immunology
Kai P. Hoefig, Vigo Heissmeyer
CURRENT OPINION IN IMMUNOLOGY
(2008)
Article
Immunology
Katharina U. Vogel, Stephanie L. Edelmann, Katharina M. Jeltsch, Arianna Bertossi, Klaus Heger, Gitta A. Heinz, Jessica Zoeller, Sebastian C. Warth, Kai P. Hoefig, Claudia Lohs, Frauke Neff, Elisabeth Kremmer, Joel Schick, Dirk Repsilber, Arie Geerlof, Helmut Blum, Wolfgang Wurst, Mathias Heikenwaelder, Marc Schmidt-Supprian, Vigo Heissmeyer
Article
Virology
Jia Yun Zhu, Martin Strehle, Anne Frohn, Elisabeth Kremmer, Kai P. Hoefig, Gunter Meister, Heiko Adler
JOURNAL OF VIROLOGY
(2010)
Article
Immunology
Elke Glasmacher, Kai P. Hoefig, Katharina U. Vogel, Nicola Rath, Lirui Du, Christine Wolf, Elisabeth Kremmer, Xiaozhong Wang, Vigo Heissmeyer
Article
Biochemistry & Molecular Biology
Kai P. Hoefig, Nicola Rath, Gitta A. Heinz, Christine Wolf, Jasmin Dameris, Aloys Schepers, Elisabeth Kremmer, K. Mark Ansel, Vigo Heissmeyer
NATURE STRUCTURAL & MOLECULAR BIOLOGY
(2013)
Article
Oncology
Merle Hanke, Kai Hoefig, Hartmut Merz, Alfred C. Feller, Ingo Kausch, Dieter Jocham, Jens M. Warnecke, Georg Sczakiel
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2010)
Article
Oncology
Hartmut Merz, Christian Kaehler, Kai P. Hoefig, Biggi Branke, Wolfgang Uckert, Roger Nadrowitz, Sabine-Cerny-Reiterer, Harald Herrmann, Alfred C. Feller, Peter Valent
Review
Cell Biology
Kai P. Hoefig, Vigo Heissmeyer
WILEY INTERDISCIPLINARY REVIEWS-RNA
(2014)
Article
Multidisciplinary Sciences
Kai P. Hoefig, Alexander Reim, Christian Gallus, Elaine H. Wong, Gesine Behrens, Christine Conrad, Meng Xu, Lisa Kifinger, Taku Ito-Kureha, Kyra A. Y. Defourny, Arie Geerlof, Josef Mautner, Stefanie M. Hauck, Dirk Baumjohann, Regina Feederle, Matthias Mann, Michael Wierer, Elke Glasmacher, Vigo Heissmeyer
Summary: Post-transcriptional gene regulation in T cells is a dynamic and complex process, involving multiple RNA-binding proteins and unexpected functions for certain transcription factors and signal transducers. By studying the regulation of Roquin-1 and Roquin-2, it was found that multiple RBPs contribute to the coregulation of mRNA targets by individual trans-acting factors.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Tiantom Jarutat, Cora Nickels, Christian Frisch, Florian Stellmacher, Kai Peter Hofig, Achim Knappik, Hartmut Merz
BIOLOGICAL CHEMISTRY
(2007)
Article
Oncology
Kai P. Hoefig, Christoph Thorns, Anja Roehle, Christian Kaehler, Kai O. Wesche, Dirk Repsilber, Biggi Branke, Marlen Thiere, Alfred C. Feller, Hartmut Merz
ANTICANCER RESEARCH
(2008)